Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Collaborator: Otsuka America Pharmaceutical
• Treatments: Aripiprazole; Quetiapine Fumarate; Risperidone

Criteria

Inclusion Criteria:

• Patient with diagnosis of chronic Schizophrenia or Schizoaffective disorder

• Stable symptoms and dose of Quetiapine or Risperidone

Exclusion Criteria:

• First diagnosis in the past year

• Significant risk of suicide or meet DSM-IV-TR criteria for substance abuse